Stem Cell Therapy Market: Growth, Size, Share, and Trends

Rising regulatory approvals are strengthening confidence in stem cell therapy as a commercially viable treatment class rather than only an experimental area of regenerative medicine. Approvals of products such as Ryoncil, Omisirge, cord blood-derived HSPC products, and gene-modified HSPC therapies show that regulators are willing to approve stem/progenitor-cell therapies when clinical benefit, safety, manufacturing control, and quality standards are demonstrated. This is encouraging biopharma companies, hospitals, investors, and CDMOs to expand activity in MSC therapies, HSPC therapies, iPSC-derived products, and tissue-engineered regenerative therapies. In December 2024, the FDA approved Ryoncil as the first mesenchymal stromal cell therapy in the US, which is a major validation point for MSC-based products. These approvals are also helping improve physician awareness, payer discussions, clinical-trial activity, and commercial readiness across the stem cell therapy market.

High therapy price and uncertain reimbursement remain major barriers because stem cell therapies often require complex cell sourcing, individualized or batch-based manufacturing, GMP facilities, release testing, cryopreservation, logistics, hospitalization, specialist administration, and long-term follow-up. Autologous and gene-modified stem cell therapies are especially expensive because they involve patient-specific collection, manufacturing, conditioning, chain-of-identity control, and specialized treatment-center infrastructure. Even when a therapy is clinically effective, adoption can remain limited if hospitals are uncertain about payment, payers restrict coverage, or patients face access barriers. The need for outcomes-based reimbursement models highlights that payers want clearer evidence of long-term durability and cost offset before supporting broad use. CMS’s Cell and Gene Therapy Access Model, initially focused on sickle cell disease gene therapies, reflects this market challenge by linking access and payment more closely to outcomes and provider data submission.

iPSC-derived therapies represent one of the most important long-term opportunities in the stem cell therapy market because they can potentially enable scalable, standardized, allogeneic, off-the-shelf cell replacement products. Unlike many autologous therapies, iPSC-derived platforms can be developed from master cell banks and differentiated into specific therapeutic cell types such as dopaminergic neural progenitors, cardiomyocytes, retinal cells, pancreatic beta-like cells, and other specialized cells. This could expand the market into large, high-unmet-need indications such as Parkinson’s disease, heart failure, diabetes, retinal degeneration, and other chronic degenerative disorders. In March 2026, Sumitomo Pharma announced conditional and time-limited approval in Japan for an allogeneic iPSC-derived product for Parkinson’s disease, marking an important commercial milestone for iPSC-based regenerative medicine. However, the opportunity will depend on proving long-term safety, consistency of differentiation, tumorigenicity control, immune compatibility, and reimbursement feasibility.

Potency testing and product characterization are major challenges because stem cell therapies are living, heterogeneous, and highly sensitive to donor source, culture conditions, passage number, differentiation state, cryopreservation, and manufacturing changes. Unlike conventional drugs, the active mechanism of stem cell products may involve multiple functions, including engraftment, differentiation, paracrine signaling, immunomodulation, tissue repair, or hematopoietic reconstitution. This makes it difficult to design a single potency assay that reliably predicts clinical performance across every batch. Developers must demonstrate identity, purity, viability, sterility, genetic stability, potency, and batch-to-batch comparability, especially when scaling from clinical to commercial manufacturing. FDA’s guidance on potency assurance and manufacturing comparability shows that regulators view these issues as central to the successful development and approval of human cellular and gene therapy products.